Literature DB >> 15187513

Multifactorial risk analysis of bone marrow histiocytic hyperplasia with hemophagocytosis in critically ill medical patients--a postmortem clinicopathologic analysis.

Richard Strauss1, Daniel Neureiter, Bert Westenburger, Markus Wehler, Thomas Kirchner, Eckhart G Hahn.   

Abstract

OBJECTIVE: Systematic studies of the prevalence and risk factors of histiocytic hyperplasia with hemophagocytosis (HHH) in critically ill patients are lacking. The aim of our study was a) to determine the frequency and intensity of HHH in the bone marrow of patients who died on the medical intensive care unit; b) to analyze morphologic bone marrow changes; and c) to identify possible risk factors and their interactions in the pathogenesis of HHH.
DESIGN: A retrospective observational analysis of clinical data and autopsy findings including histologic and immunohistological analysis of bone marrow to characterize cellularity, siderosis, hemophagocytosis, and T-cell infiltrates.
SETTING: The medical intensive care unit of a university hospital. PATIENTS: Patients were 107 consecutive patients who died and underwent autopsy.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: HHH was identified in 69 of the 107 patients (64.5%). Moderate to severe HHH was present in 35 of the 107 bone marrows. Univariate risk factor analysis showed that HHH was associated with various intrinsic and extrinsic factors. However, multivariate analysis identified the intensity of therapeutic interventions--represented by the Therapeutic Intervention Scoring System--as the only positive, and cardiovascular disease as the only significant negative, predictor of HHH (p <.05). Routine laboratory tests were of no value in predicting the presence of HHH. The intensity of HHH correlated significantly with siderosis and T-cell infiltrates (p <.05) but not with bone marrow cellularity.
CONCLUSIONS: HHH is common in medical intensive care unit nonsurvivors. Treatment intensity and a noncardiovascular cause of death are predictors of HHH. Sepsis and blood transfusion may have a synergistic effect on the triggering of HHH. HHH in bone marrow is associated with enhanced T-cell infiltrates, suggesting that T cells may play an important role in its mediation.

Entities:  

Mesh:

Year:  2004        PMID: 15187513     DOI: 10.1097/01.ccm.0000127779.24232.15

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  38 in total

1.  Why and How Is Hyperferritinemic Sepsis Different From Sepsis Without Hyperferritinemia?

Authors:  Joseph A Carcillo; Kate K Kernan; Christopher M Horvat; Dennis W Simon; Rajesh K Aneja
Journal:  Pediatr Crit Care Med       Date:  2020-05       Impact factor: 3.624

2.  The Unexpected Evolution of an Expected Complication: Hemophagocytic Lymphohistiocytosis.

Authors:  Annamaria Agnes; Cosimo Callari; Marco Raffaelli
Journal:  Obes Surg       Date:  2017-01       Impact factor: 4.129

3.  IL-1 receptor antagonist in sepsis: new findings with old data?

Authors:  David Grimaldi; Eduardo Wilfrido Goicoechea Turcott; Fabio Silvio Taccone
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

Review 4.  Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Childhood Inflammatory Disorders: Diagnosis and Management.

Authors:  Lauren A Henderson; Randy Q Cron
Journal:  Paediatr Drugs       Date:  2020-02       Impact factor: 3.022

5.  Hemophagocytic syndrome caused by primary herpes simplex virus 1 infection: report of a first case.

Authors:  A Cusini; H F Günthard; G Stussi; U Schwarz; T Fehr; E Grueter; A Meerbach; W Bossart; D J Schaer; A Rudiger
Journal:  Infection       Date:  2010-07-03       Impact factor: 3.553

6.  Understanding Disseminated Intravascular Coagulation and Hepatobiliary Dysfunction Multiple Organ Failure in Hyperferritinemic Critical Illness.

Authors:  Joseph A Carcillo; Bita Shakoory; Dennis Simon; Kate Kernan
Journal:  Pediatr Crit Care Med       Date:  2018-10       Impact factor: 3.624

7.  Circulating levels of the shed scavenger receptor sCD163 and association with outcome of critically ill patients.

Authors:  Catherine Ingels; Holger J Møller; Troels K Hansen; Pieter J Wouters; Ilse Vanhorebeek; Greet Van den Berghe
Journal:  J Clin Immunol       Date:  2012-11-13       Impact factor: 8.317

Review 8.  What nephrologists need to know about hemophagocytic syndrome.

Authors:  Alexandre Karras
Journal:  Nat Rev Nephrol       Date:  2009-06       Impact factor: 28.314

9.  Hemophagocytic syndrome in patients with acute myeloid leukemia undergoing intensive chemotherapy.

Authors:  Karen Delavigne; Emilie Bérard; Sarah Bertoli; Jill Corre; Eliane Duchayne; Cécile Demur; Véronique Mansat-De Mas; Cécile Borel; Muriel Picard; Muriel Alvarez; Audrey Sarry; Françoise Huguet; Christian Récher
Journal:  Haematologica       Date:  2013-10-18       Impact factor: 9.941

10.  Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus.

Authors:  Selin Aytaç; Ezgi Deniz Batu; Şule Ünal; Yelda Bilginer; Mualla Çetin; Murat Tuncer; Fatma Gümrük; Seza Özen
Journal:  Rheumatol Int       Date:  2016-08-10       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.